Rodd-Henricks Z A, McKinzie D L, Edmundson V E, Dagon C L, Murphy J M, McBride W J, Lumeng L, Li T K
Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis 46202-4887, USA.
Alcohol. 2000 May;21(1):73-85. doi: 10.1016/s0741-8329(00)00083-5.
Previous research indicated that 5-HT(3) antagonists can reduce ethanol drinking in rats, but drinking conditions and other environmental manipulations influenced the efficacy of these antagonists. The current experiments were conducted to examine the effects of the 5-HT(3) antagonists MDL 72222 (MDL) or ICS 205-930 (ICS) on 24-h ethanol (10% v/v) consumption during acquisition, maintenance, and following a period of deprivation in selectively bred high alcohol-preferring (P) male rats. In an analysis of the acquisition of ethanol consumption, daily injections of MDL (1 mg/kg; s.c.) or ICS (1 or 5 mg/kg) were administered to separate groups of P rats during the initial 10 days of ethanol exposure. To examine the maintenance of ethanol drinking, these same groups of rats were allowed access to ethanol for 21 days with no pharmacological manipulations, and were then administered either saline or the 5-HT(3) antagonist. To examine the effects of a 5-HT(3) antagonist on relapse of ethanol drinking, another group of P rats was allowed access to ethanol for 6 weeks and was then deprived of ethanol for 3 weeks. Prior to ethanol reinstatement, rats were treated chronically (seven daily injections) or acutely with MDL (1 mg/kg), saline, or received no injections. MDL (1 mg/kg) and ICS (1 or 5 mg/kg) reduced ethanol intake during acquisition (60-80%) and during maintenance drinking (35-70%) in P rats pretreated with saline during acquisition. However, in rats pretreated with MDL or ICS during acquisition, there was a significant reduction in the effectiveness of either MDL or ICS to reduce ongoing ethanol drinking. Neither acute nor chronic treatment with 1 mg/kg MDL altered the 80% increase in ethanol consumption observed on the first day of reinstatement following a 3-week deprivation period. However, in a follow-up study, acute treatment with MDL (3 mg/kg) or ICS (5 mg/kg) did prevent the 80% increase in ethanol consumption observed on the first day of reinstatement. Overall, the results suggest that 5-HT(3) receptors are involved in the acquisition and maintenance of 24-h ethanol drinking, and that neuroadaptations may occur as a result of chronic treatment with 5-HT(3) antagonists, or during prolonged alcohol deprivation, which alter the involvement of these receptors in regulating alcohol drinking in the P rat.
先前的研究表明,5-羟色胺3(5-HT(3))拮抗剂可减少大鼠的乙醇摄入量,但饮酒条件及其他环境因素会影响这些拮抗剂的效果。开展当前实验旨在研究5-HT(3)拮抗剂MDL 72222(MDL)或ICS 205-930(ICS)对选择性培育的高乙醇偏好(P)雄性大鼠在乙醇摄入习得期、维持期及一段禁饮期后的24小时乙醇(10% v/v)摄入量的影响。在对乙醇摄入习得情况的分析中,在乙醇暴露的最初10天里,分别对不同组的P大鼠每日皮下注射MDL(1毫克/千克)或ICS(1或5毫克/千克)。为研究乙醇饮用的维持情况,让这些相同组别的大鼠在无药物干预的情况下饮用乙醇21天,之后给予生理盐水或5-HT(3)拮抗剂。为研究5-HT(3)拮抗剂对乙醇饮用复发的影响,让另一组P大鼠饮用乙醇6周,然后禁饮3周。在乙醇复饮前,大鼠长期(每日注射7次)或急性给予MDL(1毫克/千克)、生理盐水,或不注射。在习得期用生理盐水预处理的P大鼠中,MDL(1毫克/千克)和ICS(1或5毫克/千克)在习得期(60 - 80%)和维持期饮用时(35 - 70%)均减少了乙醇摄入量。然而,在习得期用MDL或ICS预处理的大鼠中,MDL或ICS减少持续乙醇饮用的效果显著降低。在3周禁饮期后的复饮第一天,1毫克/千克MDL的急性或长期治疗均未改变观察到的乙醇摄入量增加80%的情况。然而,在一项后续研究中,MDL(3毫克/千克)或ICS(5毫克/千克)的急性治疗确实预防了复饮第一天观察到的乙醇摄入量增加80%的情况。总体而言,结果表明5-HT(3)受体参与了24小时乙醇饮用的习得和维持过程,并且慢性给予5-HT(3)拮抗剂或在长期酒精禁饮期间可能会发生神经适应性变化,这改变了这些受体在调节P大鼠酒精饮用中的作用。